secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001601830-24-000195
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion Q3 revenue $26.1M, net loss $95.8M; Exscientia merger on track
------------------------------------------------------------------------

- Revenue surged to $26.1M from $10.5M YoY; net loss $95.8M vs $93.0M; no EPS provided.
- Cash and equivalents $427.6M as of Sep 30, 2024; net cash used in operations $59.2M.
- Roche-Genentech optioned first neuroscience phenomap for $30M; total potential $500M across multiple maps.
- Proposed Exscientia merger: shareholder vote Nov 12; scheme of arrangement expected Nov 20, 2024.
- Clinical milestones: Phase 2 CCM data encouraging; IND cleared for REC-1245; first patient dosed in Phase 2 C. diff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000195/0001601830-24-000195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000195/rxrx-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer